Loading

Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology

Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology

BOCA RATON, Fla.July 12, 2018,/PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced a strategic agreement focused on marketing the SRT-100 Vision™ with SkinCure Oncology, a leading turnkey provider of IGSRT solutions in the dermatology industry. SkinCure uses the same quality and safety features of leading cancer center models for the delivery of Sensus’ most technically advanced and innovative device to date, the SRT-100 Vision, to dermatology practices.

Read the full press release here.

Share to:

Contact Us

Fill out the form below to find out more!